News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Forbion Announces Closing Of Public Offering Of Portfolio Company, Argos Therapeutics, Inc. (ARGS)


2/20/2014 8:45:47 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics (“Argos” or “the Company”) has closed its initial public offering. The initial public offering price was $8.00 per ordinary share. Argos' ordinary shares have listed on the NASDAQ Global Market and began trading under the symbol "ARGS" on 7 February 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES